GSK's cancer drug Blenrep faced FDA panel pushback over dose-related risks in multiple myeloma patients. Despite high ocular toxicity concerns, GSK cited strong DREAMM trial data showing extended survival. Stock fell 4.7% but sentiment on Stocktwits remained bullish. Traders called it a "buying opportunity," as FDA's final decision is due on July 23.